Concepedia

Peter Ordentlich

PO

48

Publications

6.3K

Citations

33

H-Index

1991

Active since

Affiliations

Synta Pharmaceuticals (United States)(Current)

Roswell Park Comprehensive Cancer Center

Dana-Farber Cancer Institute

Memorial Sloan Kettering Cancer Center

The Wistar Institute

Peter Ordentlich is an author at Synta Pharmaceuticals (United States) specializing in medicine, oncology, and cell biology.

ORCID

Top concepts

Publications per year

1991–2024

48

Publications

48

Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors

Vinit Kumar, Laxminarasimha Donthireddy, Douglas Marvel et al. · Cancer Cell · 2017 · 621 citations · Full text

, , +9

A histone deacetylase corepressor complex regulates the Notch signal transduction pathway

Hung‐Ying Kao, Peter Ordentlich, Naoko Koyano‐Nakagawa et al. · Genes & Development · 1998 · 576 citations · Full text

A Natural Product That Lowers Cholesterol As an Antagonist Ligand for FXR

Nancy L. Urizar, Amy B. Liverman, D'Nette T. Dodds et al. · Science · 2002 · 537 citations

Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression

Hung‐Ying Kao, Michael Downes, Peter Ordentlich et al. · Genes & Development · 2000 · 421 citations · Full text

, , +16

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

Ghayas C. Issa, Ibrahim Aldoss, John F. DiPersio et al. · Nature · 2023 · 420 citations · Full text

Rows per page

1–5 of 48